The case in summary: Gunn Kaya Glad was told that she had cancer in 2022, and started chemotherapy. She joined a cancer study called IMPRESS, where gene tests were taken from the tumor to identify which gene errors caused the cancer. Based on the genetic tests, a tailored course of treatment was laid, and showed good results. The Norwegian Cancer Society calls genetic testing a kind of revolution in the understanding of cancer, and has chosen genetic testing for the Swedish Cancer Society’s fundraising campaign, which runs from 4 to 10 March. The aim is for more patients with spread to receive a genetic test of the tumor earlier and the best treatment based on their cancer types. The summary is made by an AI service from OpenAi. The content is quality assured by news’s journalists before publication. – I’m not nervous. I’m excited. It is always exciting to see if it has shrunk, if it is stable or if it has started to grow. Then I have a problem. Gunn tells Kaya Glad just before she is to be examined in a CT machine. In 2022, she received the difficult message. She had cancer, and the tumor was the size of a coconut. The diagnosis was cancer of unknown origin. That made the doctors unsure about the treatment Gunn should receive. But a revolution in cancer treatment was on the way. A possible solution lay in genetic testing. Gunn Kaya Glad first started with chemotherapy, but it was only when she became part of the IMPRESS cancer study that the treatment gave encouraging results. Photo: Elisabeth Sandve / news Treatment started with heart in the throat The outlook after the diagnosis looked bad. Chief physician at Sørlandet Hospital, Christopher Müller, first started with chemotherapy. – When I met her, she was very ill, so at some point we found out that we had to start chemotherapy. We did that with our hearts in our throats, says the superintendent. But all hope was not lost. She joined a cancer study called IMPRESS, where gene tests were taken from the tumor to identify which gene errors caused the cancer. – They took blood samples and tested the genes for this cancer in Germany. Then I got involved in this cancer study, says Glad. Chief physician at Sørlandet Hospital Kristiansand, Christopher Müller recommended the cancer study for Gunn Kaya Glad. Photo: Elisabeth Sandve / news A new hope The work to treat cancer types based on the genetic characteristics of a tumor gave good prospects. It was Müller who got Gunn Kaya involved in the IMPRESS study. – Gunn Kaya has a gene defect on the surface of his cancer cells that we can block with medicine, and stop the cancer’s growth. A tailored run for treatment was made based on the genetic tests. And the tumor was shrunk from a coconut to a marble. Although she is still not fully recovered, Glad says that she has drawn the winning lottery ticket. This medicine helps to prevent Gunn Kaya Glad’s cancer from growing. Photo: Elisabeth Sandve / news Collecting money for more research The Norwegian Cancer Society calls genetic testing a kind of revolution in the understanding of cancer. Now they have chosen genetic testing for the Cancer Society’s fundraising campaign, which started on 4 March. – This can make it possible for more patients to receive treatment that is more effective and precise, and more cancer patients can live longer and live good lives, says regional manager of the Cancer Association Geir O. Wehus. The aim is for more patients with spread to receive a genetic test of the tumor earlier and then the best treatment based on the results. – We want more cancer patients with spread who benefit from it to receive this offer. Today, a thousand cancer patients with spread are offered a genetic test.
ttn-69
Gentest worked wonders – gives hope in the fight against cancer – news Sørlandet – Local news, TV and radio
